Literature DB >> 2647311

Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes.

A R Khokhar1, S al-Baker, I H Krakoff, R Perez-Soler.   

Abstract

A new series of highly lipid-soluble cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane)platinum(II) complexes were synthesized and characterized by their elemental analysis and by various spectroscopic techniques [infrared (IR), 195pt nuclear magnetic resonance (NMR)]. cis-bis-Neopentanoato(trans-R,R-1,2-diaminocyclohexane)platinum(II ) (NPDP), cis-bis-neodecanoato(trans-R,R-1,2-diaminocyclohexane)-platinum(II ) (NDDP), and cis-bis-n-decanoato(trans-R,R-1,2-diaminocyclohexane)-platinum(II) (DEDP) complexes were entrapped in multilamellar vesicles composed of dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) at a 7:3 molar ratio and tested for toxicity and antitumor activity. The entrapment efficiency of the liposomal platinum (L-Pt) complexes (L-NPDP, L-NDDP, L-DEDP) was greater than 95%, and the stability in 0.9% NaCl solution at 4 degrees C was greater than 95% at day 14 in each case. The LD50 values of L-NPDP, L-NDDP, and L-DEDP when injected i.v. were 30, 54, and 150 mg/kg, respectively. L-NPDP, L-NDDP, and L-DEDP had no significant nephrotoxicity [as evidenced by a lack of elevated blood urea nitrogen (BUN) levels]. The percentages of T/C obtained after a single i.p. injection of the optimal dose of L-NPDP, L-NDDP, and L-DEDP tested against L1210 leukemia were 175%, 187%, and 212%, respectively [160% for cisplatin (CDDP)]. When a multiple i.p. injection schedule was used (on days 1, 5, and 9), L-NPDP, L-NDDP, and L-DEDP were more active than CDDP (percentage of T/C: 312%, 312%, 277%, and 220%, respectively). When injected i.v., only L-NDDP showed significant activity against L1210 leukemia i.v. (percentage of T/C: 186%). L-NDDP and L-DEDP were markedly active against L1210 leukemia resistant to CDDP (percentage of T/C: 200% and 145% vs 112% for CDDP). L-NPDP, L-NDDP, and L-DEDP also had good activity against i.p. B16 melanoma when they were injected i.p. on days 1, 5, and 9 (percentage of T/C: 206%, 225%, and 306%, respectively). L-NDDP and L-DEDP were more effective than CDDP in inhibiting the growth of liver metastases of murine M5076 reticulosarcoma, whereas L-NPDP was not active. The results obtained to date suggest that L-NDDP is the best L-Pt-complex candidate for further developmental studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647311     DOI: 10.1007/bf00451645

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  New platinum complexes with anti-tumour activity.

Authors:  T A Connors; M Jones; W C Ross; P D Braddock; A R Khokhar; M L Tobe
Journal:  Chem Biol Interact       Date:  1972-11       Impact factor: 5.192

2.  Nephrotoxicity of cis-dichlorodiammineplatinum(II).

Authors:  I H Krakoff
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

3.  Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.

Authors:  R Perez-Soler; A R Khokhar; G Lopez-Berestein
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

4.  Mouse Lewis lung carcinoma and hepatoma ascites treatment by combination of liposome chemotherapy and non-specific immunotherapy.

Authors:  K R Patel; J D Baldeschwieler
Journal:  Int J Cancer       Date:  1984-11-15       Impact factor: 7.396

5.  Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.

Authors:  E H Herman; A Rahman; V J Ferrans; J A Vick; P S Schein
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

6.  Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin.

Authors:  E Mayhew; Y Rustum; W J Vail
Journal:  Cancer Drug Deliv       Date:  1983

7.  Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth.

Authors:  I R Hart; J E Talmadge; I J Fidler
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

8.  Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

Authors:  E A Forssen; Z A Tökès
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes.

Authors:  F Olson; E Mayhew; D Maslow; Y Rustum; F Szoka
Journal:  Eur J Cancer Clin Oncol       Date:  1982-02

10.  Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles.

Authors:  R Perez-Soler; A R Khokhar; P Claringbold; L P Kasi; G Lopez-Berestein
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

View more
  7 in total

Review 1.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

2.  Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.

Authors:  R A Schwendener; H H Fiebig; M R Berger; D P Berger
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups.

Authors:  R Perez-Soler; I Han; S al-Baker; A R Khokhar
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 5.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Liposome formulations for effective administration of lipophilic malonatoplatinum(II) complexes.

Authors:  Insook Han; Mee Sook Jun; Moon Kyu Kim; Jung Chul Kim; Youn Soo Sohn
Journal:  Jpn J Cancer Res       Date:  2002-11

Review 7.  Intracavitary therapies for mesothelioma.

Authors:  C F Verschraegen
Journal:  Curr Treat Options Oncol       Date:  2001-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.